231 related articles for article (PubMed ID: 37432548)
1. The Role of Small Interfering RNAs in Hepatocellular Carcinoma.
Chen F; Zhang W; Gao X; Yuan H; Liu K
J Gastrointest Cancer; 2024 Mar; 55(1):26-40. PubMed ID: 37432548
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic potential of small interfering RNAs/micro interfering RNA in hepatocellular carcinoma.
Farra R; Grassi M; Grassi G; Dapas B
World J Gastroenterol; 2015 Aug; 21(30):8994-9001. PubMed ID: 26290628
[TBL] [Abstract][Full Text] [Related]
3. RNA interference as therapeutics for hepatocellular carcinoma.
Xu C; Lee SA; Chen X
Recent Pat Anticancer Drug Discov; 2011 Jan; 6(1):106-15. PubMed ID: 21110827
[TBL] [Abstract][Full Text] [Related]
4. Small interfering RNA-mediated gene suppression as a therapeutic intervention in hepatocellular carcinoma.
Hajiasgharzadeh K; Somi MH; Shanehbandi D; Mokhtarzadeh A; Baradaran B
J Cell Physiol; 2019 Apr; 234(4):3263-3276. PubMed ID: 30362510
[TBL] [Abstract][Full Text] [Related]
5. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.
Varshosaz J; Farzan M
World J Gastroenterol; 2015 Nov; 21(42):12022-41. PubMed ID: 26576089
[TBL] [Abstract][Full Text] [Related]
6. Polo-like Kinase 1-targeting Chitosan Nanoparticles Suppress the Progression of Hepatocellular Carcinoma.
Wang D; Chang R; Wang G; Hu B; Qiang Y; Chen Z
Anticancer Agents Med Chem; 2017; 17(7):948-954. PubMed ID: 27671301
[TBL] [Abstract][Full Text] [Related]
7. Strategies to optimize siRNA delivery to hepatocellular carcinoma cells.
Scarabel L; Perrone F; Garziera M; Farra R; Grassi M; Musiani F; Russo Spena C; Salis B; De Stefano L; Toffoli G; Rizzolio F; Tonon F; Abrami M; Chiarappa G; Pozzato G; Forte G; Grassi G; Dapas B
Expert Opin Drug Deliv; 2017 Jun; 14(6):797-810. PubMed ID: 28266887
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumor activity of KNTC2 siRNA in orthotopic tumor model mice of hepatocellular carcinoma.
Makita Y; Murata S; Katou Y; Kikuchi K; Uejima H; Teratani M; Hoashi Y; Kenjo E; Matsumoto S; Nogami M; Otake K; Kawamata Y
Biochem Biophys Res Commun; 2017 Nov; 493(1):800-806. PubMed ID: 28843857
[TBL] [Abstract][Full Text] [Related]
9. An RGD-modified MRI-visible polymeric vector for targeted siRNA delivery to hepatocellular carcinoma in nude mice.
Wu C; Gong F; Pang P; Shen M; Zhu K; Cheng D; Liu Z; Shan H
PLoS One; 2013; 8(6):e66416. PubMed ID: 23922634
[TBL] [Abstract][Full Text] [Related]
10. Theranostical nanosystem-mediated identification of an oncogene and highly effective therapy in hepatocellular carcinoma.
Guo Y; Wang J; Zhang L; Shen S; Guo R; Yang Y; Chen W; Wang Y; Chen G; Shuai X
Hepatology; 2016 Apr; 63(4):1240-55. PubMed ID: 26680504
[TBL] [Abstract][Full Text] [Related]
11. Advances in liver-directed gene therapy for hepatocellular carcinoma by non-viral delivery systems.
Ding B; Li T; Zhang J; Zhao L; Zhai G
Curr Gene Ther; 2012 Apr; 12(2):92-102. PubMed ID: 22348553
[TBL] [Abstract][Full Text] [Related]
12. The role of micro-RNAs in hepatocellular carcinoma: from molecular biology to treatment.
D'Anzeo M; Faloppi L; Scartozzi M; Giampieri R; Bianconi M; Del Prete M; Silvestris N; Cascinu S
Molecules; 2014 May; 19(5):6393-406. PubMed ID: 24853455
[TBL] [Abstract][Full Text] [Related]
13. RNA interference against granulin-epithelin precursor prevents hepatocellular carcinoma growth: its application as a therapeutic agent.
Park MY; Park YS; Nam JH
Int J Oncol; 2011 Oct; 39(4):853-61. PubMed ID: 21701774
[TBL] [Abstract][Full Text] [Related]
14. Downregulating hypoxia-inducible factor-2α improves the efficacy of doxorubicin in the treatment of hepatocellular carcinoma.
He C; Sun XP; Qiao H; Jiang X; Wang D; Jin X; Dong X; Wang J; Jiang H; Sun X
Cancer Sci; 2012 Mar; 103(3):528-34. PubMed ID: 22145922
[TBL] [Abstract][Full Text] [Related]
15. Combination of Nanoparticle-Delivered siRNA for Astrocyte Elevated Gene-1 (AEG-1) and All-trans Retinoic Acid (ATRA): An Effective Therapeutic Strategy for Hepatocellular Carcinoma (HCC).
Rajasekaran D; Srivastava J; Ebeid K; Gredler R; Akiel M; Jariwala N; Robertson CL; Shen XN; Siddiq A; Fisher PB; Salem AK; Sarkar D
Bioconjug Chem; 2015 Aug; 26(8):1651-61. PubMed ID: 26079152
[TBL] [Abstract][Full Text] [Related]
16. miR-221 suppression through nanoparticle-based miRNA delivery system for hepatocellular carcinoma therapy and its diagnosis as a potential biomarker.
Li F; Wang F; Zhu C; Wei Q; Zhang T; Zhou YL
Int J Nanomedicine; 2018; 13():2295-2307. PubMed ID: 29713162
[TBL] [Abstract][Full Text] [Related]
17. M6A-mediated upregulation of LINC00958 increases lipogenesis and acts as a nanotherapeutic target in hepatocellular carcinoma.
Zuo X; Chen Z; Gao W; Zhang Y; Wang J; Wang J; Cao M; Cai J; Wu J; Wang X
J Hematol Oncol; 2020 Jan; 13(1):5. PubMed ID: 31915027
[TBL] [Abstract][Full Text] [Related]
18. Cationic lipid nanoparticles for therapeutic delivery of siRNA and miRNA to murine liver tumor.
Hsu SH; Yu B; Wang X; Lu Y; Schmidt CR; Lee RJ; Lee LJ; Jacob ST; Ghoshal K
Nanomedicine; 2013 Nov; 9(8):1169-80. PubMed ID: 23727126
[TBL] [Abstract][Full Text] [Related]
19. Polymer-Mediated Delivery of siRNAs to Hepatocellular Carcinoma: Variables Affecting Specificity and Effectiveness.
Farra R; Musiani F; Perrone F; Čemažar M; Kamenšek U; Tonon F; Abrami M; Ručigaj A; Grassi M; Pozzato G; Bonazza D; Zanconati F; Forte G; El Boustani M; Scarabel L; Garziera M; Russo Spena C; De Stefano L; Salis B; Toffoli G; Rizzolio F; Grassi G; Dapas B
Molecules; 2018 Mar; 23(4):. PubMed ID: 29597300
[TBL] [Abstract][Full Text] [Related]
20. Golgi membrane protein GP73 modified-liposome mediates the antitumor effect of survivin promoter-driven HSVtk in hepatocellular carcinoma.
Liu C; Wen C; Wang X; Wei Y; Xu C; Mu X; Zhang L; Wang X; Tian J; Ma P; Meng F; Zhang Q; Zhao N; Yu B; Gong T; Guo R; Wang H; Xie J; Sun G; Li G; Zhang H; Qin Q; Xu J; Dong X; Wang L
Exp Cell Res; 2019 Oct; 383(1):111496. PubMed ID: 31306654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
